Dashboard: Filter Bricks
Main page content
This brochure gives an overview of the Mental Health Parity and Addiction Equity Act of 2008. It lists some of the common limits placed on mental health and substance use disorder benefits and services.
This document provides an overview of essential information necessary for understanding mental health and substance use disorder parity and how to implement and comply with federal parity laws. This guide applies to parity laws in employer-sponsored health plans and group and individual insurance.
There are protections in federal law, collectively known as “parity,” which are designed to ensure that certain types of health plans cover mental and substance use disorders no less generously than they cover other health issues. This resource can guide you to helpful materials and places.
This updated TIP includes the latest evidence on motivation-enhancing approaches and strategies. It describes how substance use disorder treatment providers can use these approaches and strategies to increase participation and retention in substance use disorder treatment.
Esta hoja informativa se puede usar como una guía para las personas que buscan tratamiento de salud mental. Ofrece tres pasos necesarios para llevar a cabo antes de utilizar un centro de tratamiento, así como las cinco señales de un centro de tratamiento de calidad, que incluye revisar la acreditación, la medicación, las prácticas basadas en la evidencia, el papel de las familias y las redes de apoyo.
This fact sheet serves as a guide for individuals seeking behavioral health treatment. It provides three necessary steps to complete prior to utilizing a treatment center and the five signs of a quality treatment center, which include a review of the accreditation, medication, evidence-based practices, position on the role of families, and support networks.
This report offers best practices for implementing the Mental Health Parity and Addiction Equity Act of 2008. It covers processes for implementing parity and collaborating with other organizations. The report also discusses tools for understanding and monitoring compliance.
This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.
Displaying 1 - 10 out of 19